Lab
Mount Sinai Medical Center of Florida, INC
Mount Sinai Medical Center of Florida, INC was paid $18.30M by Medicaid between Jan 2018 and Dec 2024, across 276 billing codes. Its largest line is 99284, emergency room visit (serious) — 15% of everything it billed.
33Billing provider infoMOUNT SINAI MEDICAL CENTER OF FLORIDA, INC
MIAMI BEACH, FL 33140
MIAMI BEACH, FL 33140
33aNPI1912964768assigned 04/26/2006
33bProvider typeClinical Medical Laboratory
28Total paid$18.30M
24GClaims1,023,527
24DCodes billed276
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Florida
Rank by total paid#8 of 225
Median peer was paid$74K
This provider vs. median249×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 90,154 | $1.45M | |
| 2019 | 209,303 | $2.77M | |
| 2020 | 156,996 | $2.28M | |
| 2021 | 210,384 | $3.45M | |
| 2022 | 218,281 | $4.43M | |
| 2023 | 92,235 | $2.74M | |
| 2024incomplete | 46,174 | $1.18M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 46,956 | 37,824 | $2.81M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 35,816 | 30,146 | $2.48M |
| 96361 | Intravenous infusion, hydration; each additional hour | 8.2% | 19,686 | 15,090 | $1.50M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.2% | 30,419 | 23,148 | $1.50M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.7% | 6,216 | 4,855 | $680K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.5% | 8,181 | 7,177 | $640K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.4% | 4,856 | 3,731 | $445K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.2% | 6,167 | 4,798 | $405K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2.1% | 11,990 | 8,705 | $389K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 6,064 | 4,486 | $358K |
| 80053 | Comprehensive metabolic panel | 1.7% | 38,021 | 23,800 | $303K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.4% | 14,778 | 7,887 | $264K |
264 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.3% | 29,324 | $230K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.2% | 2,875 | $214K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.2% | 5,531 | $211K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 78,437 | $209K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.1% | 1,700 | $204K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.1% | 34,763 | $196K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.0% | 19,154 | $189K |
| G0378 | Hospital observation service, per hour | <1% | 11,492 | $182K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 26,925 | $162K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,921 | $159K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 16,940 | $158K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 13,642 | $158K |
| 36415 | Collection of venous blood by venipuncture | <1% | 20,188 | $149K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 6,365 | $145K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 648 | $138K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,864 | $133K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,137 | $125K |
| 87631 | <1% | 6,690 | $117K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 4,391 | $116K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,345 | $113K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,453 | $109K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,486 | $99K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,087 | $97K |
| 76641 | <1% | 5,396 | $87K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 454 | $87K |
| 70498 | <1% | 1,076 | $86K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,843 | $82K |
| 76770 | <1% | 1,712 | $78K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,603 | $75K |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 1,156 | $74K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 5,649 | $73K |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 166 | $73K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 14,755 | $70K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,281 | $63K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 5,321 | $61K |
| 87088 | <1% | 22,414 | $56K | |
| 80076 | <1% | 10,005 | $53K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,144 | $52K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,979 | $51K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 8,834 | $46K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,989 | $45K |
| 10060 | <1% | 681 | $43K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,742 | $43K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,987 | $42K |
| 71045 | Radiologic examination, chest; single view | <1% | 11,939 | $38K |
| J2704 | Injection, propofol, 10 mg | <1% | 8,550 | $37K |
| 77066 | Tomosynthesis, mammo | <1% | 1,756 | $36K |
| 81025 | <1% | 11,992 | $35K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 23,746 | $34K |
| 73610 | <1% | 1,609 | $32K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 104 | $31K |
| 76830 | Ultrasound, transvaginal | <1% | 2,048 | $31K |
| 85610 | <1% | 17,855 | $31K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,978 | $31K |
| 85730 | <1% | 16,466 | $28K | |
| C1769 | Guide wire | <1% | 2,700 | $28K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,262 | $26K |
| 86850 | <1% | 2,299 | $26K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,133 | $26K |
| 72131 | <1% | 1,134 | $26K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 687 | $25K |
| 86900 | <1% | 3,109 | $25K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,165 | $25K |
| 83615 | <1% | 2,270 | $25K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,566 | $25K |
| 71250 | <1% | 2,057 | $24K | |
| 85027 | <1% | 2,531 | $24K | |
| J3490 | Unclassified drugs | <1% | 12,923 | $23K |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 1,532 | $22K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,790 | $22K |
| 93970 | <1% | 1,213 | $21K | |
| 93971 | <1% | 1,938 | $20K | |
| 83735 | <1% | 3,522 | $19K | |
| 73130 | <1% | 1,526 | $19K | |
| 73630 | <1% | 1,936 | $18K | |
| 73562 | <1% | 2,542 | $18K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,970 | $17K |
| 12001 | <1% | 315 | $17K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,483 | $17K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,402 | $16K |
| 81001 | <1% | 15,891 | $16K | |
| 84439 | <1% | 1,881 | $16K | |
| 87077 | <1% | 4,422 | $16K | |
| 77065 | Tomosynthesis, mammo | <1% | 956 | $16K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 877 | $15K |
| 80061 | Lipid panel | <1% | 3,458 | $15K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 493 | $15K |
| 74178 | <1% | 220 | $15K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 977 | $14K |
| 96417 | <1% | 873 | $14K | |
| 76801 | <1% | 1,823 | $14K | |
| 84484 | <1% | 16,607 | $14K | |
| 73110 | <1% | 1,139 | $13K | |
| 84702 | <1% | 3,155 | $13K | |
| 73030 | <1% | 2,169 | $13K | |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 86 | $12K |
| 76536 | <1% | 379 | $12K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 2,457 | $11K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,676 | $11K |
| 87081 | <1% | 593 | $11K | |
| 81003 | <1% | 11,894 | $10K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,330 | $10K |
| 83690 | <1% | 13,156 | $10K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 2,095 | $10K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,196 | $9K |
| 86901 | <1% | 3,055 | $8K | |
| 88304 | <1% | 539 | $8K | |
| 12011 | <1% | 118 | $8K | |
| 87070 | <1% | 836 | $8K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,265 | $8K |
| 82728 | <1% | 3,030 | $8K | |
| 70486 | <1% | 201 | $8K | |
| 77080 | <1% | 572 | $7K | |
| 70496 | <1% | 999 | $7K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 409 | $7K |
| 83540 | <1% | 2,548 | $7K | |
| 83550 | <1% | 2,520 | $7K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,012 | $7K |
| 87040 | <1% | 4,380 | $6K | |
| 93458 | <1% | 99 | $6K | |
| 74174 | <1% | 76 | $6K | |
| 96415 | <1% | 310 | $6K | |
| 82607 | <1% | 2,239 | $6K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13,291 | $6K |
| 82746 | <1% | 1,876 | $6K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 95 | $6K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,137 | $5K |
| 74018 | <1% | 437 | $5K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,926 | $5K |
| 83605 | <1% | 6,100 | $5K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,912 | $5K |
| 97161 | <1% | 439 | $4K | |
| 74183 | <1% | 52 | $4K | |
| 73080 | <1% | 453 | $4K | |
| 96367 | <1% | 360 | $4K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 308 | $4K |
| 83880 | <1% | 3,945 | $4K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 719 | $4K |
| 87205 | <1% | 1,412 | $4K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,451 | $3K |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 2,198 | $3K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 322 | $3K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 40 | $3K |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 17 | $3K |
| 84481 | <1% | 453 | $3K | |
| 87186 | <1% | 3,788 | $3K | |
| 73502 | <1% | 892 | $3K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 793 | $3K |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 186 | $3K |
| 88300 | <1% | 552 | $3K | |
| 72197 | <1% | 18 | $3K | |
| 93017 | <1% | 164 | $3K | |
| 96376 | <1% | 1,826 | $3K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,532 | $3K |
| 72100 | <1% | 347 | $3K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 468 | $3K |
| 76775 | <1% | 142 | $2K | |
| 87075 | <1% | 455 | $2K | |
| 85379 | <1% | 2,071 | $2K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 570 | $2K |
| 72110 | <1% | 417 | $2K | |
| 76870 | <1% | 110 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,599 | $2K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 216 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,944 | $2K |
| 84153 | <1% | 532 | $2K | |
| 90715 | <1% | 1,461 | $2K | |
| 88342 | <1% | 1,203 | $2K | |
| 73140 | <1% | 127 | $2K | |
| 82565 | <1% | 759 | $2K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 80 | $2K |
| 12002 | <1% | 59 | $2K | |
| 85045 | <1% | 132 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,692 | $2K |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 324 | $1K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,406 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,824 | $1K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 754 | $1K |
| 82378 | <1% | 86 | $1K | |
| 84520 | <1% | 467 | $1K | |
| 83970 | <1% | 426 | $1K | |
| 72040 | <1% | 84 | $1K | |
| 71101 | <1% | 60 | $1K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,615 | $1K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 569 | $1K |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 302 | $1K |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 88 | $976.72 |
| 82550 | <1% | 1,801 | $881.58 | |
| 84100 | <1% | 1,325 | $851.43 | |
| 96368 | <1% | 41 | $822.39 | |
| 72141 | <1% | 20 | $792.37 | |
| 94726 | <1% | 63 | $762.56 | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 73 | $666.30 |
| 84550 | <1% | 1,102 | $660.21 | |
| 86140 | <1% | 1,089 | $639.01 | |
| C1893 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away | <1% | 98 | $610.22 |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 105 | $590.40 |
| 82272 | <1% | 250 | $563.65 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 117 | $560.25 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 64 | $559.03 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 72 | $546.08 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,773 | $542.18 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 2,042 | $532.87 |
| 74221 | <1% | 17 | $505.80 | |
| 84165 | <1% | 183 | $500.41 | |
| 96401 | <1% | 36 | $498.70 | |
| 97116 | <1% | 234 | $453.44 | |
| 51702 | <1% | 21 | $444.36 | |
| 93925 | <1% | 17 | $362.57 | |
| 85652 | <1% | 568 | $353.74 | |
| 73660 | <1% | 17 | $340.33 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 48 | $317.26 |
| 82570 | <1% | 581 | $316.44 | |
| 82784 | <1% | 92 | $313.81 | |
| 77336 | <1% | 51 | $276.73 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 265 | $230.16 |
| 87045 | <1% | 36 | $227.74 | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 50 | $207.81 |
| 74019 | <1% | 35 | $196.47 | |
| 84156 | <1% | 270 | $173.47 | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 133 | $143.60 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 359 | $141.61 |
| C1758 | Catheter, ureteral | <1% | 148 | $129.42 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 67 | $129.42 |
| 00813 | <1% | 238 | $106.54 | |
| 94729 | <1% | 66 | $86.97 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 180 | $79.05 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,131 | $77.06 |
| 00812 | <1% | 100 | $74.45 | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 279 | $63.54 |
| 86592 | <1% | 46 | $54.28 | |
| 00731 | <1% | 42 | $51.53 | |
| 87340 | <1% | 204 | $46.08 | |
| 86300 | <1% | 55 | $41.39 | |
| 73090 | <1% | 30 | $39.57 | |
| 80069 | <1% | 114 | $34.02 | |
| 94010 | <1% | 21 | $33.43 | |
| 82248 | <1% | 819 | $28.10 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 476 | $21.59 |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 67 | $15.44 |
| 86704 | <1% | 46 | $9.31 | |
| 86706 | <1% | 50 | $9.31 | |
| 73060 | <1% | 16 | $5.81 | |
| 82043 | <1% | 31 | $0.06 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 457 | $0.00 |
| 87147 | 0% | 151 | $0.00 | |
| 87449 | 0% | 52 | $0.00 | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 0% | 14 | $0.00 |
| 83883 | 0% | 20 | $0.00 | |
| 85651 | 0% | 36 | $0.00 | |
| 97165 | 0% | 17 | $0.00 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 19 | $0.00 |
| J7799 | Noc drugs, other than inhalation drugs, administered through dme | 0% | 17 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 369 | $0.00 |
| 84145 | 0% | 19 | $0.00 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 68 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 15 | $0.00 |
| 87324 | 0% | 35 | $0.00 | |
| J2720 | Injection, protamine sulfate, per 10 mg | 0% | 19 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 13 | $0.00 |
| 29125 | 0% | 14 | $0.00 | |
| 73590 | 0% | 45 | $0.00 | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | 0% | 18 | $0.00 |
| 87177 | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCHUTKAN, WAYNE (VICE PRESIDENT OF FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Physician Practices of MSMC, LLC | Miami Beach, FL | $964K |
| Radiology of MSMC, LLC | Miami Beach, FL | $415K |
| MSMC Neonatology, LLC | Miami, FL | $230K |
| Mount Sinai Intensivists LLC | Miami Beach, FL | $10K |
| Radiology of MSMC, LLC | Hialeah, FL | $7K |
| MSMC Interventional, LLC | Miami Beach, FL | $686.97 |
| Cardiology of the Florida Keys, LLC | Key West, FL | $212.42 |
| MSMC Oncology, LLC | Miami Beach, FL | $0.00 |
| MSMC of the Florida Keys, LLC | Key West, FL | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.